Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01901094 · ClinicalTrials.gov registry record · Phase 3
Comparison of Axillary Lymph Node Dissection with Axillary Radiation for Patients with Node-Positive Breast Cancer Treated with Chemotherapy
A Phase 3 study of Stage II Breast Cancer and Stage IIIA Breast Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Active
- Registry status
- Phase 3
- Development phase
- 2,012
- Enrollment target
- 20
- Study locations
NCT01901094 is a Phase 3 study of Stage II Breast Cancer and Stage IIIA Breast Cancer that is active but no longer recruiting, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 2,012 participants, above the 252-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (698% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT01901094, a Phase 3 study of Stage II Breast Cancer and Stage IIIA Breast Cancer, is active but no longer recruiting, sponsored by Alliance for Clinical Trials in Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,012 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase III trial studies lymph node dissection and radiation therapy to see how well it works compared to radiation therapy alone in treating patients with breast cancer previously treated with chemotherapy and surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x rays or protons to kill tumor cells. It is not yet known if radiation therapy works better alone or with lymph node dissection in treating patients with breast cancer previously treated with chemotherapy and surgery.
Conditions Studied
Interventions
- PROCEDURE Axillary Lymph Node Dissection (ALND)
- RADIATION Nodal Radiation Therapy
- RADIATION Axillary Radiation Therapy
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Regional Hospital - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
- Fairbanks Memorial Hospital - Fairbanks
Alabama
- Southern Cancer Center PC-Daphne - Daphne
- Mobile Infirmary Medical Center - Mobile
- Southern Cancer Center PC-Mobile - Mobile
- Southern Cancer Center PC-Providence - Mobile
- Southern Cancer Center PC-Springhill - Mobile
- University of South Alabama Mitchell Cancer Institute - Mobile
Arizona
- Arizona Breast Cancer Specialists-Gilbert - Gilbert
- Virginia G Piper Cancer Care-Glendale - Glendale
- Arizona Center for Cancer Care-Peoria - Peoria
- Cancer Center at Saint Joseph's - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,012 participants |
| Start Date | 2014-02-24 |
| Est. Completion | 2026-01-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01901094
The ClinicalTrials.gov registry entry for NCT01901094 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 2,012 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 252-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (698% higher). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stage II Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Axillary Lymph Node Dissection (ALND) is the first listed.
NCT01901094 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Alaska, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT01901094 about?
NCT01901094 is a clinical study titled "Comparison of Axillary Lymph Node Dissection with Axillary Radiation for Patients with Node-Positive Breast Cancer Treated with Chemotherapy". This randomized phase III trial studies lymph node dissection and radiation therapy to see how well it works compared to radiation therapy alone in treating patients with breast cancer previously treated with chemotherapy and surgery. Lymph node dissection may remove cancer cells that have spread to...
What is the current status of trial NCT01901094?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 2,012 participants. The study started on 2014-02-24. Estimated completion is 2026-01-01.
What conditions does trial NCT01901094 study?
This clinical trial studies the following conditions: Stage II Breast Cancer, Stage IIIA Breast Cancer.
What interventions are being tested in trial NCT01901094?
The interventions under investigation include: Axillary Lymph Node Dissection (ALND) (PROCEDURE), Nodal Radiation Therapy (RADIATION), Axillary Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT01901094?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01901094 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage II Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
-
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
ACTIVE NOT RECRUITING · Phase 3
-
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
COMPLETED · Phase 3
-
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
RECRUITING · NA
-
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.